Attendees in San Diego will experience new program features, educational offerings, and networking opportunities—all intended to enhance the overall Scientific Sessions experience, said Marlon Pragnell, PhD, ADA Vice President of Research & Science. More debates, audience polling, and extended time for questions are among the additions. Read more

Carrying extra weight exacerbates diabetes and can lead to a variety of metabolic and biomechanical complications. In SURMOUNT 2, a GLP-1/GIP dual receptor agonist led to weight loss in patients with both obesity and type 2 diabetes to an extent previously unseen. Investigators including W. Timothy Garvey, MD, will present trial results at the Scientific Sessions. Read more

The COORDINATE-Diabetes trial studied the effects of prescribing three recommended classes of drugs to patients with both type 2 diabetes and atherosclerotic disease compared to standard care. Investigators including Neha Pagidipati, MD, MPH, will review the results in a Scientific Sessions symposium. Read more

A panel of diabetes and cardiovascular experts, including Jan Borén, MD, PhD, will discuss cardiovascular disease and people with diabetes. The symposium will cover contributing factors to cardiovascular residual risk, new drug targets, and methods to assess disease. Read more

For many years, rural residents in the United States were healthier as a population than their urban counterparts. In the 1980s, that began to change. Four researchers, including Vasan Ramachandran, MD, DM, FACC, FAHA, will discuss this trend in the context of diabetes diagnosis and care. Read more